One Team, One Study: Building High-Performance Sponsor-CRO Partnerships Across the Clinical Trial Lifecycle

Strategic Oncology CRO Partnership: Advancing a First-in-Human Glioblastoma Study to Phase II

Sponsor Profile

A research-driven, clinical-stage drug delivery company developing a novel, localised glioblastoma therapy sought an experienced, oncology-focused CRO to support its first clinical trial. While the underlying science was strong, launching an oncology trial that required not only protocol optimisation, but also regulatory positioning, inspection readiness, and operational execution to successfully advance into clinical development.

Case study | Ref: CS006 | February 2026

Aixial’s Approach: Integrated Scientific, Regulatory and Operational Leadership

Aixial engaged early, building rapport through scientific depth and regulatory credibility. Rather than entering a formal bid defence process, by demonstrating immediate value through collaborative protocol refinement and proactive strategic guidance.

Working as an extension of the sponsor’s team, Aixial:

Reviewed and optimised the draft protocol, advising on study design, operational feasibility, and regulatory considerations
Co-developed and finalised the full clinical protocol
Prepared the Scientific Advice briefing package for submission to the Medicines and Healthcare products Regulatory Agency (MHRA)
Provided strategic guidance to ensure regulatory readiness and long-term development objectives
Structured a flexible commercial model aligned with the sponsor’s financial realities, reinforcing our long-term partnership approach
Supported corporate positioning and external stakeholder communications to strengthen investor and partner engagement

This integrated approach ensured the programme was not only operationally executable, but regulator-ready and strategically positioned for expansion.

Why This Strategic Partnership Matters

Our collaboration with the Sponsor represents more than a service agreement. We have a strategic alliance built on shared ambition and complementary expertise:

Patient-centred execution: By combining innovation with operational rigour, we enabled ethical, efficient study activation across clinical sites.
Deep therapeutic innovation: Our sponsor brings a groundbreaking therapy to transform the treatment of glioblastoma
Specialist oncology expertise: Aixial contributes deep experience in neuro-oncology, rare disease, and complex regulatory environments
Regulatory confidence: Together, we refined the development pathway to meet regulatory expectations and support future marketing authorisation strategy

Measurable Outcomes: From First-Time Sponsor to Phase II-Ready company

The collaboration resulted in measurable progress:

Timely Scientific Advice submission to regulators
Successful initiation of the Phase I First-In-Human study
Site activation within projected timelines
Implementation of a structured sponsor governance framework
Clear pathway and operational readiness for Phase II expansion

Together, we have enabled the sponsor to move from concept to clinical execution, advancing a potentially transformative therapy for glioblastoma and positioning the programme for continued development.